These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38482760)

  • 1. [Difficult-to-treat rheumatoid arthritis].
    Alromaih FJ; Dumusc A
    Rev Med Suisse; 2024 Mar; 20(865):541-545. PubMed ID: 38482760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment.
    Novella-Navarro M; Cabrera-Alarcón J; López-Juanes N; Villalba A; Fernández Fernández E; Monjo I; Peiteado D; Nuño L; Plasencia-Rodríguez C; Balsa A
    RMD Open; 2023 Sep; 9(3):. PubMed ID: 37775112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital.
    Hecquet S; Combier A; Steelandt A; Pons M; Wendling D; Molto A; Miceli-Richard C; Allanore Y; Avouac J
    Rheumatology (Oxford); 2023 Dec; 62(12):3866-3874. PubMed ID: 36961324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EULAR definition of difficult-to-treat rheumatoid arthritis.
    Nagy G; Roodenrijs NMT; Welsing PM; Kedves M; Hamar A; van der Goes MC; Kent A; Bakkers M; Blaas E; Senolt L; Szekanecz Z; Choy E; Dougados M; Jacobs JW; Geenen R; Bijlsma HW; Zink A; Aletaha D; Schoneveld L; van Riel P; Gutermann L; Prior Y; Nikiphorou E; Ferraccioli G; Schett G; Hyrich KL; Mueller-Ladner U; Buch MH; McInnes IB; van der Heijde D; van Laar JM
    Ann Rheum Dis; 2021 Jan; 80(1):31-35. PubMed ID: 33004335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid arthritis.
    Di Matteo A; Bathon JM; Emery P
    Lancet; 2023 Nov; 402(10416):2019-2033. PubMed ID: 38240831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
    Smolen JS; Landewé R; Breedveld FC; Buch M; Burmester G; Dougados M; Emery P; Gaujoux-Viala C; Gossec L; Nam J; Ramiro S; Winthrop K; de Wit M; Aletaha D; Betteridge N; Bijlsma JW; Boers M; Buttgereit F; Combe B; Cutolo M; Damjanov N; Hazes JM; Kouloumas M; Kvien TK; Mariette X; Pavelka K; van Riel PL; Rubbert-Roth A; Scholte-Voshaar M; Scott DL; Sokka-Isler T; Wong JB; van der Heijde D
    Ann Rheum Dis; 2014 Mar; 73(3):492-509. PubMed ID: 24161836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.
    Tan Y; Buch MH
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification.
    Novella-Navarro M; Ruiz-Esquide V; Torres-Ortiz G; Chacur CA; Tornero C; Fernández-Fernández E; Monjo I; Sanmartí R; Plasencia-Rodríguez C; Balsa A
    Clin Exp Rheumatol; 2023 May; 41(5):1114-1119. PubMed ID: 36377568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
    Nagy G; Roodenrijs NMT; Welsing PMJ; Kedves M; Hamar A; van der Goes MC; Kent A; Bakkers M; Pchelnikova P; Blaas E; Senolt L; Szekanecz Z; Choy EH; Dougados M; Jacobs JW; Geenen R; Bijlsma JW; Zink A; Aletaha D; Schoneveld L; van Riel P; Dumas S; Prior Y; Nikiphorou E; Ferraccioli G; Schett G; Hyrich KL; Mueller-Ladner U; Buch MH; McInnes IB; van der Heijde D; van Laar JM
    Ann Rheum Dis; 2022 Jan; 81(1):20-33. PubMed ID: 34407926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Difficult Rheumatology Diagnosis.
    Devaraj NK
    Ethiop J Health Sci; 2018 Jan; 28(1):101-102. PubMed ID: 29622913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.
    Conran C; Kolfenbach J; Kuhn K; Striebich C; Moreland L
    Curr Rheumatol Rep; 2023 Dec; 25(12):285-294. PubMed ID: 37776482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.
    Lee YC; Cui J; Lu B; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME; Solomon DH
    Arthritis Res Ther; 2011 Jun; 13(3):R83. PubMed ID: 21651807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing patients with resistant rheumatoid arthritis.
    Madden J
    Nurs Stand; 2008 Jul 2-8; 22(43):51-7; quiz 58. PubMed ID: 18655507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
    Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
    Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hider SL; Bruce IN; Silman AJ; Symmons DP
    J Rheumatol; 2005 Jan; 32(1):6-10. PubMed ID: 15630715
    [No Abstract]   [Full Text] [Related]  

  • 16. Perioperative Management of Immunosuppressive Medications for Rheumatoid Arthritis.
    Hresko AM; Got CJ; Gil JA
    J Hand Surg Am; 2022 Apr; 47(4):370-378. PubMed ID: 35184919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
    Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.
    Roodenrijs NMT; Hamar A; Kedves M; Nagy G; van Laar JM; van der Heijde D; Welsing PMJ
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33419871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis.
    Lau CS; Chia F; Dans L; Harrison A; Hsieh TY; Jain R; Jung SM; Kishimoto M; Kumar A; Leong KP; Li Z; Lichauco JJ; Louthrenoo W; Luo SF; Mu R; Nash P; Ng CT; Suryana B; Wijaya LK; Yeap SS
    Int J Rheum Dis; 2019 Mar; 22(3):357-375. PubMed ID: 30809944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological management of rheumatoid arthritis: the state of the art and the future perspective].
    Kameda H; Takeuchi T
    Nihon Rinsho; 2013 Jul; 71(7):1166-71. PubMed ID: 23961662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.